Obicetrapib (NewAmsterdam Pharma / A. Menarini, private) — high cardiovascular risk dyslipidemia (elevated LDL-C, or "bad cholesterol," despite existing treatment)

• What it is: An oral pill designed to lower LDL-C (low-density lipoprotein cholesterol — the "bad" cholesterol linked to heart attack risk) in patients who still have dangerously high cholesterol despite taking maximum doses of existing therapies; it is being tested head-to-head against bempedoic acid (a non-statin oral cholesterol-lowering pill already on the market).
• Who it moves: This is a threat read for AstraZeneca (AZN). AZN markets Farxiga and co-promotes the PCSK9-inhibitor (a powerful injectable cholesterol-lowering drug class) franchise, but more directly, AZN sells Crestor (rosuvastatin — a widely used statin cholesterol pill) generically and has cardiovascular portfolio exposure; critically, a strong obicetrapib win here validates a new oral cholesterol-lowering entrant that competes for the same statin-intolerant, high-risk patient pool that AZN's cardiovascular franchise targets — however, AZN's most material cholesterol-adjacent revenue today is not large enough to make this a primary AZN mover, and the competitive overlap is real but not a top-tier revenue threat.
• Catalyst & timing: The primary endpoint — percentage change in LDL-C from baseline to Day 84 (approximately 12 weeks) versus bempedoic acid — is expected to read out around January 2027, based on the stated primary completion date.
• Size of the prize: No credible consensus peak-sales figure is publicly established for obicetrapib at this stage; the addressable pool is large (millions of statin-intolerant or residual-risk patients in the U.S. and Europe), but commercial sizing will depend heavily on this and other ongoing Phase 3 outcomes.

SKIP: The competitive overlap with AZN is not material enough to AZN's current revenue base to warrant a full teach-in entry; AZN's cholesterol franchise (legacy Crestor generics) is not a top-line driver, and obicetrapib's primary competitive read-through is to bempedoic acid's owner (Esperion Therapeutics) and the broader oral LDL-lowering market rather than to AZN specifically.

---

*Correction to format above — given the materiality assessment, the proper response is:*

SKIP: Obicetrapib's head-to-head versus bempedoic acid (a non-statin cholesterol pill) is most directly a threat to Esperion Therapeutics, not AZN; AZN's cholesterol-related revenue is not a material driver of the stock, so this trial does not create a meaningful AZN exposure.

Reformulated PG324 (Alcon Research, ALC.SW / SIX-listed; no major US ticker) — open-angle glaucoma (OAG — a common form of glaucoma where fluid builds up and damages the optic nerve) / ocular hypertension (OHT — elevated eye pressure that raises glaucoma risk)

• What it is: A reformulated once-daily eye drop combining two proven pressure-lowering agents into a single bottle, designed to reduce the tolerability problems (chiefly eye redness) that have limited uptake of the original fixed-dose combination.
• Who it moves: This is a direct threat to Glaukos (GKOS), whose iDose TR (a sustained-release implant that continuously delivers a pressure-lowering drug inside the eye) competes for the same OAG/OHT patients. GKOS's iDose TR is a premium-priced, procedure-based alternative to daily drops; a reformulated combination drop that is better tolerated and equally effective would give ophthalmologists a compelling reason to keep patients on drops rather than escalating to a surgical implant, which is the exact step-up where iDose TR captures revenue. iDose TR is a key near-term revenue growth driver for GKOS, so any headwind to drop-to-device conversion matters materially to the stock's growth narrative.
• Catalyst & timing: The trial's primary completion date is April 6, 2026, meaning top-line IOP (intraocular pressure — the fluid pressure inside the eye, the key efficacy readout in glaucoma trials) data are expected around mid-2026. If Alcon reports strong efficacy with meaningfully improved tolerability versus the original PG324 (Roclanda/Rhopressa combo), that is the signal to watch for GKOS; a clear tolerability win for the reformulation would reinforce the "stay on drops" physician mindset, while a neutral or negative result would remove a competitive overhang.
• Size of the prize: The global glaucoma drug market is approximately $6–7 billion annually and growing; a well-tolerated fixed-dose combination drop from a major surgical/device company like Alcon could credibly reach $500 million–$1 billion in peak sales if it displaces incumbent combinations, though no public consensus estimate exists for this specific reformulation. The at-risk patient pool is large — roughly 80 million people worldwide have glaucoma, with OHT affecting tens of millions more — so the addressable market is meaningful context for the competitive pressure on GKOS's device-conversion thesis.

Donanemab (Eli Lilly, LLY) — Alzheimer's Disease (early cognitive decline)

• What it is: An already-approved Alzheimer's antibody infusion (donanemab clears amyloid plaques — abnormal protein deposits in the brain) now being tested in patients at the very earliest detectable stage of cognitive decline, before a full Alzheimer's diagnosis is established.
• Who it moves: This is an LLY-owned asset, so a positive readout would expand the addressable market for donanemab well beyond its current approved label, potentially pulling in a large earlier-stage population; a null result would cap the drug's commercial ceiling at the already-approved, more advanced patient pool and limit the next leg of revenue growth for what is already one of LLY's key franchises.
• Catalyst & timing: Primary completion is August 2028, with CDR-SB (Clinical Dementia Rating – Sum of Boxes, a standard measure of thinking and daily functioning) data expected around that time or shortly after; this is a Phase 2 trial (mid-stage, designed to establish proof of concept and dosing before a larger confirmatory study) with 350 participants enrolled.
• Size of the prize: Donanemab (branded Kisunla) already carries consensus peak-sales estimates in the range of ~$5–7 billion annually in its approved indication; a successful extension into early/pre-symptomatic Alzheimer's — where the potential patient population is meaningfully larger — could add several billion dollars on top of that, though no credible analyst estimate specific to this earlier population yet exists given the trial is still mid-course.

Tirzepatide & Retatrutide (Eli Lilly, LLY) — MASLD/NASH liver-outcomes trial

• What it is: Two of Lilly's injectable weight-loss and metabolic medicines being tested to see whether they can prevent serious liver deterioration — such as cirrhosis (permanent scarring) or liver failure — in patients with MASLD (metabolic dysfunction-associated steatotic liver disease, formerly called NASH or non-alcoholic fatty liver disease, a condition where excess fat damages the liver).
• Who it moves: This is squarely an LLY-owned story. Tirzepatide (Mounjaro/Zepbound — Lilly's already-approved diabetes and obesity injection) is the commercial anchor, and a positive outcomes result here would expand its label into a major new chronic-disease indication; retatrutide (Lilly's next-generation metabolic candidate still in development) is being tested alongside it, giving Lilly a potential two-asset franchise in liver disease. A win validates MASLD as a durable new revenue pillar layered on top of the existing obesity/diabetes business; a miss or safety signal would remove a widely anticipated growth avenue and pressure the long-term earnings trajectory.
• Catalyst & timing: The primary completion date is August 2030, meaning top-line MALO (major adverse liver outcomes — a composite of hard clinical events like cirrhosis progression, liver transplant, or liver-related death) results are unlikely before late 2030 at the earliest, with a roughly 224-week (approximately 4.5-year) treatment period for enrolled participants; no interim readout dates are disclosed in the trial record.
• Size of the prize: The addressable population is large — an estimated 15–20 million Americans have advanced or high-risk MASLD, and global prevalence is substantially higher; credible analyst estimates for the MASLD drug market broadly range from $10–20 billion in peak annual sales across the class, with Lilly potentially capturing a leading share given tirzepatide's existing commercial infrastructure; no Lilly-specific peak-sales figure has been formally guided, but this indication is widely treated by the buy side as one of the largest remaining growth options for the franchise beyond obesity and diabetes.

Duvakitug (Sanofi, SNY) — Crohn's Disease

• What it is: A targeted injection designed to reduce gut inflammation in patients with moderate-to-severe Crohn's Disease (CD — a chronic inflammatory bowel condition that damages the digestive tract), representing Sanofi's bid to enter one of pharma's most lucrative inflammation franchises.
• Who it moves: SNY is the direct holder, but the bigger read-through is competitive pressure on AbbVie (ABBV), whose Skyrizi (risankizumab — an approved biologic injection for Crohn's Disease) currently leads the CD market, and on Johnson & Johnson (JNJ) with Tremfya (guselkumab — another approved biologic). A duvakitug Phase 3 win would give SNY a credible challenger in a space where ABBV derives a growing share of its immunology revenue; a failure removes a threat. Watch also Pfizer (PFE) and Takeda (TAK), which have CD assets of their own.
• Catalyst & timing: The pivotal maintenance sub-study primary completion is August 2029, with the co-primary endpoint being the proportion of patients achieving clinical remission (CDAI — a standardized score measuring CD symptom severity) at Week 40. Interim recruitment milestones and any induction-phase data readouts before 2029 could serve as earlier market-moving signals.
• Size of the prize: The global CD biologics market is on track toward ~$15B+ annually by the late 2020s, with Skyrizi alone tracking toward blockbuster CD peak sales; a differentiated entrant capturing even a mid-single-digit share represents several hundred million dollars in incremental revenue. Roughly 1.5–2 million patients in the US and Europe have moderate-to-severe CD, the addressable population here.

Balcinrenone/Dapagliflozin (AstraZeneca, AZN) — Chronic Kidney Disease (Stage 3b/4)

• What it is: A once-daily oral pill combining two kidney-protecting agents into a single tablet for patients with moderately-to-severely reduced kidney function — CKD (chronic kidney disease — a progressive loss of kidney filtering capacity) Stages 3b and 4 represent eGFR (estimated glomerular filtration rate — a measure of how well kidneys filter waste) of 15–45, a population historically excluded from most trials and left with few options beyond standard of care.
• Who it moves: This is squarely an AstraZeneca (AZN) story. Dapagliflozin (Farxiga — AZ's flagship kidney/heart pill, already approved for CKD) is one of AZ's largest revenue drivers, generating roughly $3B+ annually. Balcinrenone (an investigational add-on agent targeting excess aldosterone activity — a hormone that accelerates kidney damage) is AZ's proprietary compound; a positive BalanceD-CKD readout would extend Farxiga's commercial life, open a harder-to-treat patient segment currently underserved, and create a new fixed-dose combination franchise that competitors cannot easily replicate given AZ's ownership of both components.
• Catalyst & timing: Primary completion is July 2030, with the composite endpoint (cardiovascular death, kidney failure, sustained ≥50% eGFR decline, and heart failure events) requiring 2,800 patients. The trial is not yet recruiting, so meaningful interim data or enrollment updates are unlikely before 2026–2027 at earliest; the key data event is the primary readout around mid-2030.
• Size of the prize: Ballpark peak sales for a successful fixed-dose combination in this indication could reach $2B–$3B+ incrementally on top of existing Farxiga revenue — the CKD Stage 3b/4 population numbers in the tens of millions globally, is poorly served, and carries high rates of cardiovascular and kidney failure events that payers will pay to prevent. The Street is likely under-modeling this asset given the trial is pre-recruitment and the combination label does not yet exist; a successful outcome would represent a material, durable revenue extension for AZN's renal franchise into the 2030s.

Duvakitug (Sanofi, SNY) — Ulcerative Colitis (UC — a chronic inflammatory bowel disease causing ulcers in the colon lining)

• What it is: A targeted injectable antibody designed to put UC into long-term remission (symptom-free disease control) by blocking a specific inflammatory signaling pathway (dual TL1A inhibition, details aside).
• Who it moves: Sanofi (SNY) is the primary exposure — a Phase 3 win here would add a meaningful new pillar to its immunology franchise. The bigger read-through, however, is competitive: AbbVie (ABBV), whose Skyrizi (a gut inflammation antibody) and Rinvoq (an oral inflammation pill) currently dominate the UC market, would face a credible new entrant if duvakitug demonstrates best-in-class remission rates. Roivant Sciences (ROIV), which co-developed the TL1A (the inflammatory target) class via Telavant before selling rights to Roche/Genentech, has already partially crystallized value here — but a Sanofi success validates the entire TL1A-in-IBD thesis and keeps pressure on the incumbents.
• Catalyst & timing: The pivotal maintenance sub-study primary completion is September 2028, meaning top-line clinical remission data by modified Mayo Score (mMS — a standardized scoring tool physicians use to measure UC disease activity) should read out around that time, with potential earlier interim signals.
• Size of the prize: The UC biologics market already exceeds $10 billion annually across competitors; credible analyst estimates place peak sales potential for a best-in-class TL1A in IBD (inflammatory bowel disease — umbrella term covering UC and Crohn's disease) in the $3–5 billion range across indications, supported by a US UC patient population of roughly 1 million with moderate-to-severe disease.

Berobenatide (Pfizer, PFE) — overweight/obesity with type 2 diabetes (T2D — a condition where the body cannot properly regulate blood sugar)

• What it is: A weekly injectable weight-loss drug (delivered by a shot under the skin) that Pfizer is testing head-to-head against placebo in roughly 950 adults who are overweight or obese, including those with T2D.
• Who it moves: This is a direct read on PFE's ability to compete in the GLP-1 weight-loss space (the red-hot class of injectable drugs pioneered by Novo Nordisk's semaglutide and Eli Lilly's tirzepatide). PFE has repeatedly tried and so far failed to establish a credible obesity franchise; berobenatide is now the company's most advanced injectable obesity candidate, and Phase 3 success or failure will materially shape whether PFE can generate a meaningful revenue stream in what analysts broadly size as a $100B+ global obesity drug market by the early 2030s. The Street currently gives PFE essentially no credit for obesity, so positive efficacy data would represent a genuine upside surprise to consensus models.
• Catalyst & timing: The trial is not yet recruiting as of this writing; primary completion is listed as May 2028, meaning meaningful weight-loss efficacy data would most likely surface in late 2027 or mid-2028. Investors should watch for enrollment initiation and any interim conference presentations as nearer-term signposts.
• Size of the prize: Ballpark peak sales for a successful obesity injectable are credibly in the $3–5B+ range for a late-entry competitor with differentiated efficacy — the global obesity drug market supports multiple large franchises given ~650 million obese adults worldwide. The T2D-with-obesity subpopulation alone numbers in the hundreds of millions globally, providing a large addressable patient base. The key variable is whether berobenatide's weight-loss magnitude proves competitive with already-approved agents; without that data, the revenue estimate carries wide uncertainty.

KarXT (Bristol-Myers Squibb, BMY) — psychosis associated with Alzheimer's disease

• What it is: An already-approved oral antipsychotic pill (branded Cobenfy, approved for schizophrenia in 2024) now being tested to control hallucinations and delusions in Alzheimer's patients — a meaningfully different and larger population than its current approved use.
• Who it moves: BMY acquired Karuna Therapeutics (and with it, KarXT/Cobenfy) for ~$14 billion in early 2024, so the Alzheimer's psychosis indication is a key part of the deal's return-on-investment logic. Alzheimer's-associated psychosis (AAP — hallucinations and delusions occurring in roughly 30–50% of the ~6 million U.S. Alzheimer's patients) has no FDA-approved treatment today, making a positive readout a potential label expansion that materially changes Cobenfy's revenue trajectory. The Street is likely under-modeling this indication given the drug is still primarily discussed in the context of schizophrenia (a market analysts peg at ~$2–3B peak sales); AAP could be comparably or more valuable if the trial succeeds.
• Catalyst & timing: The primary endpoint is change from baseline in the NPI-C: H+D score (a standardized clinician rating of hallucinations and delusions severity) in 325 enrolled patients; primary completion is currently projected for February 2028, making a data readout most likely in 2028 or an FDA filing in 2028–2029.
• Size of the prize: Ballpark peak sales estimates for an approved AAP treatment range as high as $3–5B given the size of the patient pool (~1.5–3 million U.S. Alzheimer's patients experiencing psychosis at any given time) and the absence of any approved competitor — though that figure carries wide uncertainty at Phase 3 initiation and the 2028 timeline means it is not yet in near-term consensus models.